Global Anal Fissure Treatment Market Research Report Forecast to 2023

$4,450$6,250

Clear

Description

Anal Fissure Treatment Market Research Report: by Treatment Type (Medication, Surgery), by Route of Administration (Oral, Topical), by End-user (Hospitals & Clinics, Research & Academic Institutes), and Region – Global Forecast till 2023
Market analysis

Anal fissures are tears in the anus lining area. They normally happen while passing heavy stools. Indications of anal fissures incorporate pain amid and after defecations. Despite the fact that they are basic in newborn, they can show up at any age. Less normal reasons for these gaps incorporate syphilis, Crohn’s disease, tuberculosis, HIV, anal cancer, and other inflammatory bowel diseases. The extensive pediatric and geriatric masses is the essential driver of the market attributable to their helplessness. The high rate of obstruction among patients is another noticeable market driver. As indicated by the American Gastroenterological Association, almost 60% Americans experience the ill effects of this condition. Medicines required for quick recuperating is probably going to help the anal fissure treatment market development exponentially. In any case, the nearness of alternative treatment choices to mitigate the pain of crevices and a quick fall in repayment plans with respect to the condition can represent a test to the market. The market is expected to reach the valuation of USD 2,526.5 million by the year 2023, by growing at a CAGR of 7.6% during the forecast period (2018- 2023).

Market segmentation

Based on its treatment type, the market is bifurcated into surgery and medication. On the basis of its routes of administration, the market is segmented into topical, oral, and others.

Regional analysis

Geographically, the Global Anal Fissure Treatment Market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

AstraZeneca (U.K.), Allergan Inc. (U.S.), Valeant Pharmaceuticals International Inc (Canada), and Taro Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc (U.K.), Cook (U.S.), Cigna (U.S.), Eisai Co. Ltd. (Japan), Abbott Laboratories (U.S.), Bayer AG (Germany), among others are some of the major players in the Global Anal Fissure Treatment Market.

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 List of Assumptions
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Overview
5.2 Drivers
5.2.1 Rising prevalence of hypertension
5.2.2 Growing initiatives by private and government organizations
5.2.3 Rise in the prevalence rates of chronic diseases
5.2.4 Increasing penetration of generic versions of drugs
5.3 Restraints
5.3.1 Side-effects of treatment options
5.3.2 High cost of treatment
5.3.3 Loss of patents
5.3.4 Rise in non-pharmacological therapy
5.4 Opportunity
5.4.1 Emerging therapies in the treatment hypertension
6 Market Factor Analysis
6.1 Value chain analysis
6.1.1 R&D and Designing
6.1.2 Manufacturing
6.1.3 Distribution & Sales
6.1.4 Post Sales Review
6.2 Porter’s Five Forces Model
6.2.1 Bargaining Power of Suppliers
6.2.1 Bargaining Power of Buyers
6.2.2 Threat of New Entrants
6.2.3 Threat of Substitutes
6.2.4 Intense Rivalry
6.3 Investment Opportunities
6.4 Pricing Analysis
7 Global Antihypertensive Drugs Market, by Therapeutic Class
7.1 Overview
7.2 Diuretics
7.3 ACE Inhibitors
7.4 ARBs
7.5 Calcium Channel Blockers
7.6 Beta-Adrenergic Blockers
7.7 Renin Inhibitors
7.8 Vasodilators
7.9 Others
8 Global Antihypertensive Drugs Market, by Type
8.1 Overview
8.2 Primary Hypertension
8.3 Secondary Hypertension
9 Global Antihypertensive Drugs Market, by Distribution Channel
9.1 Overview
9.2 Retail Pharmacy
9.3 Hospital Pharmacy
9.4 E-commerce Websites & Online Drug Stores
9.5 Others
10 Global Antihypertensive Drugs Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 UK
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
11 Competitive Landscape
11.1 Overview
11.2 Company Share Analysis
12 Company Profile
12.1 Sanofi S. A.
12.1.1 Company Overview
12.1.2 Financial Overview
12.1.3 Products Offered
12.1.4 SWOT Analysis
12.1.5 Key Developments
12.1.6 Key strategy
12.2 Novartis AG
12.2.1 Company Overview
12.2.2 Financial Overview
12.2.3 Products Offered
12.2.4 SWOT Analysis
12.2.5 Key Developments
12.2.6 Key strategy
12.3 AstraZeneca
12.3.1 Company Overview
12.3.2 Financial Overview
12.3.3 Products Offered
12.3.4 SWOT Analysis
12.3.5 Key Developments
12.3.6 Key strategy
12.4 Daiichi Sankyo Company, Ltd
12.4.1 Company Overview
12.4.2 Financial Overview
12.4.3 Products Offered
12.4.4 SWOT Analysis
12.4.5 Key Developments
12.4.6 Key Strategy
12.5 Boehringer Ingelheim GmbH
12.5.1 Company Overview
12.5.2 Financial Overview
12.5.3 Products Offered
12.5.4 SWOT Analysis
12.5.5 Key Developments
12.5.6 Key Strategy
12.6 Takeda Pharmaceutical Company Ltd
12.6.1 Company Overview
12.6.2 Financial Overview
12.6.3 Products Offered
12.6.4 SWOT Analysis
12.6.5 Key Developments
12.6.6 Key Strategy
12.7 Merck KGaA
12.7.1 Company Overview
12.7.2 Financial Overview
12.7.3 Products Offered
12.7.4 SWOT Analysis
12.7.5 Key Developments
12.7.6 Key Strategy
12.8 Johnson & Johnson Services, Inc.
12.8.1 Company Overview
12.8.2 Financial Overview
12.8.3 Products Offered
12.8.4 SWOT Analysis
12.8.5 Key Developments
12.8.6 Key Strategy
12.9 Bayer AG
12.9.1 Company Overview
12.9.2 Financial Overview
12.9.3 Products Offered
12.9.4 SWOT Analysis
12.9.5 Key Developments
12.9.6 Key Strategy
12.1 Pfizer, Inc.
12.10.1 Company Overview
12.10.2 Financial Overview
12.10.3 Products Offered
12.10.4 SWOT Analysis
12.10.5 Key Developments
12.10.6 Key Strategy
12.11 United Therapeutics Corporation
12.11.1 Company Overview
12.11.2 Financial Overview
12.11.3 Products Offered
12.11.4 SWOT Analysis
12.11.5 Key Developments
12.11.6 Key Strategy
13 Appendix
13.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format